Structure-based drug design for G protein-coupled receptors.
暂无分享,去创建一个
[1] P. Leeson,et al. The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.
[2] Miles Congreve,et al. The impact of GPCR structures on pharmacology and structure‐based drug design , 2010, British journal of pharmacology.
[3] V. Cherezov,et al. Crystallizing membrane proteins using lipidic mesophases , 2009, Nature Protocols.
[4] K. Jacobson,et al. Truncated Nucleosides as A(3) Adenosine Receptor Ligands: Combined 2-Arylethynyl and Bicyclohexane Substitutions. , 2012, ACS medicinal chemistry letters.
[5] J. Ballesteros,et al. [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .
[6] C. Higgs,et al. Hydration Site Thermodynamics Explain SARs for Triazolylpurines Analogues Binding to the A2A Receptor. , 2010, ACS medicinal chemistry letters.
[7] Sohita Dhillon. Tesamorelin , 2011, Drugs.
[8] S. Moro,et al. New insight into adenosine receptors selectivity derived from a novel series of [5-substituted-4-phenyl-1,3-thiazol-2-yl] benzamides and furamides. , 2013, European journal of medicinal chemistry.
[9] S. Moro,et al. Exploring the directionality of 5-substitutions in a new series of 5-alkylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine as a strategy to design novel human a(3) adenosine receptor antagonists. , 2012, Journal of medicinal chemistry.
[10] R. Lefkowitz,et al. Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors. , 2012, Annual review of pharmacology and toxicology.
[11] S. Rasmussen,et al. The structure and function of G-protein-coupled receptors , 2009, Nature.
[12] H. Schiöth,et al. The Adhesion GPCRs: A unique family of G protein-coupled receptors with important roles in both central and peripheral tissues , 2007, Cellular and Molecular Life Sciences.
[13] E. Novellino,et al. 3-aryl-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one: a novel template for the design of highly selective A₂B adenosine receptor antagonists. , 2012, Journal of medicinal chemistry.
[14] M. Congreve,et al. Fragment-based lead discovery , 2004, Nature Reviews Drug Discovery.
[15] Bryan L. Roth,et al. Structure of the human smoothened receptor bound to an antitumour agent , 2013, Nature.
[16] Ruben Abagyan,et al. The GPCR Network: a large-scale collaboration to determine human GPCR structure and function , 2012, Nature Reviews Drug Discovery.
[17] E. Hulme,et al. GPCR activation: a mutagenic spotlight on crystal structures. , 2013, Trends in pharmacological sciences.
[18] S. Moro,et al. Synthesis and biological evaluation of a new series of 1,2,4-triazolo[1,5-a]-1,3,5-triazines as human A(2A) adenosine receptor antagonists with improved water solubility. , 2011, Journal of medicinal chemistry.
[19] M. Burghammer,et al. Crystal structure of the human β2 adrenergic G-protein-coupled receptor , 2007, Nature.
[20] M. Rosenkilde,et al. Rational design of conformationally constrained cyclopentapeptide antagonists for C-x-C chemokine receptor 4 (CXCR4). , 2012, Journal of medicinal chemistry.
[21] T. Schwartz,et al. The minor binding pocket: a major player in 7TM receptor activation. , 2010, Trends in pharmacological sciences.
[22] X. García‐Mera,et al. Pyrimidine derivatives as potent and selective A3 adenosine receptor antagonists. , 2011, Journal of medicinal chemistry.
[23] E. Novellino,et al. New 2-heterocyclyl-imidazo[2,1-i]purin-5-one derivatives as potent and selective human A3 adenosine receptor antagonists. , 2011, Journal of medicinal chemistry.
[24] S. Moro,et al. The significance of 2-furyl ring substitution with a 2-(para-substituted) aryl group in a new series of pyrazolo-triazolo-pyrimidines as potent and highly selective hA(3) adenosine receptors antagonists: new insights into structure-affinity relationship and receptor-antagonist recognition. , 2010, Journal of medicinal chemistry.
[25] Ruben Abagyan,et al. Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. , 2010, Journal of medicinal chemistry.
[26] Krzysztof Palczewski,et al. The Significance of G Protein-Coupled Receptor Crystallography for Drug Discovery , 2011, Pharmacological Reviews.
[27] Nathan Robertson,et al. Biophysical Mapping of the Adenosine A2A Receptor , 2011, Journal of medicinal chemistry.
[28] Christopher G. Tate,et al. The structural basis for agonist and partial agonist action on a β1-adrenergic receptor , 2010, Nature.
[29] A. Gulino,et al. Vismodegib, a small-molecule inhibitor of the hedgehog pathway for the treatment of advanced cancers. , 2010, Current opinion in investigational drugs.
[30] Jonathan S. Mason,et al. Progress in Structure Based Drug Design for G Protein-Coupled Receptors , 2011, Journal of medicinal chemistry.
[31] Anthony J Harmar,et al. Family-B G-protein-coupled receptors , 2001, Genome Biology.
[32] Gregg Siegal,et al. Fragment screening of GPCRs using biophysical methods: identification of ligands of the adenosine A(2A) receptor with novel biological activity. , 2012, ACS chemical biology.
[33] Bryan L. Roth,et al. Structure of the human kappa opioid receptor in complex with JDTic , 2012, Nature.
[34] Sid Topiol,et al. Use of the X-ray structure of the Beta2-adrenergic receptor for drug discovery. , 2008, Bioorganic & medicinal chemistry letters.
[35] Amy M. Fulton,et al. The chemokine receptors CXCR4 and CXCR3 in cancer , 2009, Current oncology reports.
[36] C. Langmead,et al. Pharmacology and Structure of Isolated Conformations of the Adenosine A2A Receptor Define Ligand Efficacy , 2013, Molecular Pharmacology.
[37] R. Stevens,et al. Recent progress in the structure determination of GPCRs, a membrane protein family with high potential as pharmaceutical targets. , 2010, Methods in molecular biology.
[38] J. Holst,et al. Treatment of adult short bowel syndrome patients with teduglutide , 2012, Expert opinion on pharmacotherapy.
[39] G. Marucci,et al. Molecular modeling study on potent and selective adenosine A(3) receptor agonists. , 2010, Bioorganic & medicinal chemistry.
[40] C. Tate,et al. Thermostabilisation of an Agonist-Bound Conformation of the Human Adenosine A2A Receptor , 2011, Journal of molecular biology.
[41] R. Abagyan,et al. Molecular mechanisms deployed by virally encoded G protein-coupled receptors in human diseases. , 2013, Annual review of pharmacology and toxicology.
[42] R. Stevens,et al. Structural Features for Functional Selectivity at Serotonin Receptors , 2013, Science.
[43] T. O'Brien,et al. Fragment-based drug discovery. , 2004, Journal of medicinal chemistry.
[44] R. Stevens,et al. Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor. , 2011, Journal of medicinal chemistry.
[45] M. Caron,et al. The mammalian beta 2-adrenergic receptor: reconstitution of functional interactions between pure receptor and pure stimulatory nucleotide binding protein of the adenylate cyclase system. , 1984, Biochemistry.
[46] Miles Congreve,et al. Deal watch: Valuation benefits of structure-enabled drug discovery , 2011, Nature Reviews Drug Discovery.
[47] Francesca Deflorian,et al. Structure-guided design of A(3) adenosine receptor-selective nucleosides: combination of 2-arylethynyl and bicyclo[3.1.0]hexane substitutions. , 2012, Journal of medicinal chemistry.
[48] M. Congreve,et al. Structure of the adenosine A(2A) receptor in complex with ZM241385 and the xanthines XAC and caffeine. , 2011, Structure.
[49] Jonathan A. Javitch,et al. Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist , 2010, Science.
[50] Ruben Abagyan,et al. Optimization of adenosine 5'-carboxamide derivatives as adenosine receptor agonists using structure-based ligand design and fragment screening. , 2012, Journal of medicinal chemistry.
[51] K. Jacobson,et al. Structure-activity relationships of truncated C2- or C8-substituted adenosine derivatives as dual acting A₂A and A₃ adenosine receptor ligands. , 2012, Journal of medicinal chemistry.
[52] C. Tate,et al. Agonist-bound structures of G protein-coupled receptors. , 2012, Current opinion in structural biology.
[53] Hualiang Jiang,et al. Structural Basis for Molecular Recognition at Serotonin Receptors , 2013, Science.
[54] N. Fujii,et al. Molecular modeling study of cyclic pentapeptide CXCR4 antagonists: new insight into CXCR4-FC131 interactions. , 2012, Bioorganic & medicinal chemistry letters.
[55] Christopher G Tate,et al. A crystal clear solution for determining G-protein-coupled receptor structures. , 2012, Trends in biochemical sciences.
[56] Brian K. Shoichet,et al. Structure-Based Discovery of A2A Adenosine Receptor Ligands , 2010, Journal of medicinal chemistry.
[57] J. Mestres,et al. New chromene scaffolds for adenosine A(2A) receptors: synthesis, pharmacology and structure-activity relationships. , 2012, European journal of medicinal chemistry.
[58] A. Hopkins,et al. Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.
[59] S. Mudaliar,et al. Evolution of Exenatide as a Diabetes Therapeutic , 2013, Current diabetes reviews.
[60] Andreas Bender,et al. A prospective cross-screening study on G-protein-coupled receptors: lessons learned in virtual compound library design. , 2012, Journal of medicinal chemistry.
[61] S. Moro,et al. 2-Arylpyrazolo[4,3-d]pyrimidin-7-amino derivatives as new potent and selective human A3 adenosine receptor antagonists. Molecular modeling studies and pharmacological evaluation. , 2013, Journal of medicinal chemistry.
[62] David Rodríguez,et al. Selective and potent adenosine A3 receptor antagonists by methoxyaryl substitution on the N-(2,6-diarylpyrimidin-4-yl)acetamide scaffold. , 2013, European journal of medicinal chemistry.
[63] Z. Liu,et al. Structure-based design in the GPCR target space. , 2012, Current Medicinal Chemistry.
[64] Charles L. Brooks,et al. Community-wide assessment of GPCR structure modelling and ligand docking: GPCR Dock 2008 , 2009, Nature Reviews Drug Discovery.
[65] Hugo Gutiérrez-de-Terán,et al. Ligand-, structure- and pharmacophore-based molecular fingerprints: a case study on adenosine A1, A2A, A2B, and A3 receptor antagonists , 2012, Journal of Computer-Aided Molecular Design.
[66] Krzysztof Palczewski,et al. Vertebrate Membrane Proteins: Structure, Function, and Insights from Biophysical Approaches , 2008, Pharmacological Reviews.
[67] J. Tyndall,et al. GPCR agonists and antagonists in the clinic. , 2005, Medicinal chemistry (Shariqah (United Arab Emirates)).
[68] Ali Jazayeri,et al. Structure of class B GPCR corticotropin-releasing factor receptor 1 , 2013, Nature.
[69] L. Pardo,et al. Crystal structure of the μ-opioid receptor bound to a morphinan antagonist , 2012, Nature.
[70] Jens Carlsson,et al. Structure-activity relationships and molecular modeling of 1,2,4-triazoles as adenosine receptor antagonists. , 2012, ACS medicinal chemistry letters.
[71] R. Stevens,et al. High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein–Coupled Receptor , 2007, Science.
[72] Christopher G. Tate,et al. Biophysical Fragment Screening of the β1-Adrenergic Receptor: Identification of High Affinity Arylpiperazine Leads Using Structure-Based Drug Design , 2013, Journal of medicinal chemistry.
[73] G. Schulte,et al. The Frizzled family of unconventional G-protein-coupled receptors. , 2007, Trends in pharmacological sciences.
[74] W. Danysz,et al. Metabotropic glutamate receptors as therapeutic targets for cognitive disorders. , 2010, Current topics in medicinal chemistry.
[75] Cheng Zhang,et al. High-resolution Crystal Structure of Human Protease-activated Receptor 1 Bound to the Antagonist Vorapaxar Hhs Public Access , 2022 .
[76] S. P. Andrews,et al. Stabilised G protein-coupled receptors in structure-based drug design: a case study with adenosine A2A receptor , 2013 .
[77] T. Dinan,et al. Exciting Times beyond the Brain: Metabotropic Glutamate Receptors in Peripheral and Non-Neural Tissues , 2011, Pharmacological Reviews.
[78] John P. Overington,et al. How many drug targets are there? , 2006, Nature Reviews Drug Discovery.
[79] Albert C. Pan,et al. Structure and Dynamics of the M3 Muscarinic Acetylcholine Receptor , 2012, Nature.
[80] Martin Caffrey,et al. Membrane protein structure determination using crystallography and lipidic mesophases: recent advances and successes. , 2012, Biochemistry.
[81] Aashish Manglik,et al. Structure of the δ-opioid receptor bound to naltrindole , 2012, Nature.
[82] R. Stevens,et al. Structure-function of the G protein-coupled receptor superfamily. , 2013, Annual review of pharmacology and toxicology.
[83] Christopher G. Tate,et al. Crystal Structures of a Stabilized β1-Adrenoceptor Bound to the Biased Agonists Bucindolol and Carvedilol , 2012, Structure.
[84] Ruben Abagyan,et al. GPCR agonist binding revealed by modeling and crystallography. , 2011, TIPS - Trends in Pharmacological Sciences.
[85] D. Scott,et al. Fragment-based approaches in drug discovery and chemical biology. , 2012, Biochemistry.
[86] S. Rasmussen,et al. A monoclonal antibody for G protein–coupled receptor crystallography , 2007, Nature Methods.
[87] A. Oxford,et al. The Pharmacology of the Novel 5-HT1-Like Receptor Agonist, GR43175 , 1989, Cephalalgia : an international journal of headache.
[88] Tom L. Blundell,et al. Keynote review: Structural biology and drug discovery , 2005 .
[89] W. Delano. The PyMOL Molecular Graphics System , 2002 .
[90] Peter Kolb,et al. Limits of Ligand Selectivity from Docking to Models: In Silico Screening for A1 Adenosine Receptor Antagonists , 2012, PloS one.
[91] R. Stevens,et al. Structural Basis for Allosteric Regulation of GPCRs by Sodium Ions , 2012, Science.
[92] D. Rognan,et al. Selective structure-based virtual screening for full and partial agonists of the beta2 adrenergic receptor. , 2008, Journal of medicinal chemistry.
[93] J. Shiloach,et al. Structure of the agonist-bound neurotensin receptor , 2012, Nature.
[94] M. Congreve,et al. Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.
[95] A. Kruse,et al. Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist , 2011, Nature.
[96] G. Pairaudeau,et al. Design driven HtL: The discovery and synthesis of new high efficacy β₂-agonists. , 2011, Bioorganic & medicinal chemistry letters.
[97] N. Neamati,et al. Design of a novel cyclotide-based CXCR4 antagonist with anti-human immunodeficiency virus (HIV)-1 activity. , 2012, Journal of medicinal chemistry.
[98] X. Deupí,et al. Conserved activation pathways in G-protein-coupled receptors. , 2012, Biochemical Society transactions.
[99] B. Roth,et al. NOBEL 2012 Chemistry: Studies of a ubiquitous receptor family , 2012, Nature.
[100] E. Uriarte,et al. Discovery of novel A3 adenosine receptor ligands based on chromone scaffold. , 2012, Biochemical pharmacology.
[101] R. Abagyan,et al. Conserved binding mode of human beta2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography. , 2010, Journal of the American Chemical Society.
[102] Gregg Siegal,et al. Fragment screening of stabilized G-protein-coupled receptors using biophysical methods. , 2011, Methods in enzymology.
[103] S. Keam,et al. Teriparatide: a review of its use in osteoporosis. , 2008, Drugs.
[104] R. Rothman,et al. Serotonergic drugs and valvular heart disease , 2009, Expert opinion on drug safety.
[105] W. Spooren,et al. Allosteric Modulators for mGlu Receptors , 2007, Current neuropharmacology.
[106] Yoko Shibata,et al. Conformational thermostabilization of the β1-adrenergic receptor in a detergent-resistant form , 2008, Proceedings of the National Academy of Sciences.
[107] Dov Barak,et al. Evaluation of homology modeling of G-protein-coupled receptors in light of the A(2A) adenosine receptor crystallographic structure. , 2009, Journal of medicinal chemistry.
[108] Sébastien Granier,et al. A new era of GPCR structural and chemical biology. , 2012, Nature chemical biology.
[109] A. Bender,et al. Substructure‐Based Virtual Screening for Adenosine A2A Receptor Ligands , 2011, ChemMedChem.
[110] S. Rasmussen,et al. Structure of a nanobody-stabilized active state of the β2 adrenoceptor , 2010, Nature.
[111] Hugh Rosen,et al. Crystal Structure of a Lipid G Protein–Coupled Receptor , 2012, Science.
[112] Yoko Shibata,et al. Thermostabilisation of the neurotensin receptor NTS1 , 2009, Journal of molecular biology.
[113] Oliver P. Ernst,et al. Crystal structure of opsin in its G-protein-interacting conformation , 2008, Nature.
[114] P. Conn,et al. Metabotropic glutamate receptors: physiology, pharmacology, and disease. , 2010, Annual review of pharmacology and toxicology.
[115] Ruben Abagyan,et al. Structure of the human histamine H1 receptor complex with doxepin , 2011, Nature.
[116] H. V. van Vlijmen,et al. Identifying novel adenosine receptor ligands by simultaneous proteochemometric modeling of rat and human bioactivity data. , 2012, Journal of medicinal chemistry.
[117] Bryan L. Roth,et al. Structure of the Nociceptin/Orphanin FQ Receptor in Complex with a Peptide Mimetic , 2012, Nature.
[118] K. Varani,et al. Pyrazolo[1,5-c]quinazoline derivatives and their simplified analogues as adenosine receptor antagonists: synthesis, structure-affinity relationships and molecular modeling studies. , 2013, Bioorganic & medicinal chemistry.
[119] Jonathan S. Mason,et al. Discovery of 1,2,4-Triazine Derivatives as Adenosine A2A Antagonists using Structure Based Drug Design , 2012, Journal of medicinal chemistry.
[120] Raymond C Stevens,et al. Discovery of new GPCR biology: one receptor structure at a time. , 2009, Structure.
[121] Steven M. Moss,et al. Structural sweet spot for A1 adenosine receptor activation by truncated (N)-methanocarba nucleosides: receptor docking and potent anticonvulsant activity. , 2012, Journal of medicinal chemistry.
[122] Gebhard F. X. Schertler,et al. Structure of a β1-adrenergic G-protein-coupled receptor , 2008, Nature.
[123] Bernhard Moser,et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1 , 1996, Nature.
[124] J. Errey,et al. Preparation of purified GPCRs for structural studies. , 2013, Biochemical Society transactions.
[125] Chris de Graaf,et al. Structure of the human glucagon class B G-protein-coupled receptor , 2013, Nature.
[126] Xavier Deupi,et al. Structural insights into agonist-induced activation of G-protein-coupled receptors. , 2011, Current opinion in structural biology.
[127] Guodong Liu,et al. A G Protein-Biased Ligand at the μ-Opioid Receptor Is Potently Analgesic with Reduced Gastrointestinal and Respiratory Dysfunction Compared with Morphine , 2013, The Journal of Pharmacology and Experimental Therapeutics.
[128] R. Abagyan,et al. Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists , 2010, Science.
[129] M. Babu,et al. Molecular signatures of G-protein-coupled receptors , 2013, Nature.
[130] Peter Kolb,et al. Structure-based discovery of β2-adrenergic receptor ligands , 2009, Proceedings of the National Academy of Sciences.
[131] S. Moro,et al. Synthesis and pharmacological characterization of a new series of 5,7-disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazine derivatives as adenosine receptor antagonists: A preliminary inspection of ligand-receptor recognition process. , 2010, Bioorganic & medicinal chemistry.
[132] H. Jhoti,et al. A new school for screening , 2005, Nature Biotechnology.
[133] R. Stevens,et al. The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist , 2008, Science.
[134] José Correa-Basurto,et al. Cell-based and in-silico studies on the high intrinsic activity of two boron-containing salbutamol derivatives at the human β₂-adrenoceptor. , 2012, Bioorganic & medicinal chemistry.
[135] Nathan Robertson,et al. Article pubs.acs.org/jmc Identification of Novel Adenosine A 2A Receptor Antagonists by Virtual Screening , 2022 .
[136] T. Kenakin. Principles: receptor theory in pharmacology. , 2004, Trends in pharmacological sciences.
[137] Christopher W Murray,et al. Experiences in fragment-based drug discovery. , 2012, Trends in pharmacological sciences.
[138] Nobuhiro Yamamoto,et al. Discovery of highly potent and selective biphenylacylsulfonamide-based beta3-adrenergic receptor agonists and molecular modeling based on the solved X-ray structure of the beta2-adrenergic receptor: part 6. , 2009, Bioorganic & medicinal chemistry letters.
[139] Minyong Li,et al. Revisiting the homology modeling of G-protein coupled receptors: β1-adrenoceptor as an example. , 2012, Molecular bioSystems.
[140] Kenneth Jones,et al. Use of the X-ray structure of the beta2-adrenergic receptor for drug discovery. Part 2: Identification of active compounds. , 2008, Bioorganic & medicinal chemistry letters.
[141] S. Costanzi. Modeling G protein-coupled receptors and their interactions with ligands. , 2013, Current opinion in structural biology.
[142] Fei Xu,et al. Evaluation of molecular modeling of agonist binding in light of the crystallographic structure of an agonist-bound A₂A adenosine receptor. , 2012, Journal of medicinal chemistry.
[143] R. Stevens,et al. Structure of an Agonist-Bound Human A2A Adenosine Receptor , 2011, Science.
[144] Andrea Bortolato,et al. New insights from structural biology into the druggability of G protein-coupled receptors. , 2012, Trends in pharmacological sciences.
[145] Reuben J Pengelly,et al. Fragment Screening Using Capillary Electrophoresis (CEfrag) for Hit Identification of Heat Shock Protein 90 ATPase Inhibitors , 2012, Journal of biomolecular screening.
[146] Nathan Robertson,et al. The properties of thermostabilised G protein-coupled receptors (StaRs) and their use in drug discovery , 2011, Neuropharmacology.
[147] Stefano Costanzi,et al. Chapter 18:Structure-based Virtual Screening for Ligands of G Protein-coupled Receptors , 2011 .
[148] Patrick Scheerer,et al. Crystal structure of the ligand-free G-protein-coupled receptor opsin , 2008, Nature.
[149] Vadim Cherezov,et al. Diversity and modularity of G protein-coupled receptor structures. , 2012, Trends in pharmacological sciences.
[150] S. Rasmussen,et al. Crystal Structure of the β2Adrenergic Receptor-Gs protein complex , 2011, Nature.
[151] Yoko Shibata,et al. Co-evolving stability and conformational homogeneity of the human adenosine A2a receptor , 2008, Proceedings of the National Academy of Sciences.
[152] A. Leslie,et al. Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation , 2011, Nature.
[153] S. Moro,et al. 2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a new scaffold to obtain potent and selective human A3 adenosine receptor antagonists: new insights into the receptor-antagonist recognition. , 2009, Journal of medicinal chemistry.
[154] Michèle N Schulz,et al. Recent progress in fragment-based lead discovery. , 2009, Current opinion in pharmacology.
[155] J. Black. Drugs from emasculated hormones: the principle of syntopic antagonism. , 1989, Bioscience reports.
[156] K. Jacobson,et al. New Insights for Drug Design from the X-Ray Crystallographic Structures of G-Protein-Coupled Receptors , 2012, Molecular Pharmacology.
[157] Brian K Shoichet,et al. Structure-based drug screening for G-protein-coupled receptors. , 2012, Trends in pharmacological sciences.
[158] Monya Baker,et al. Fragment-based lead discovery grows up , 2012, Nature Reviews Drug Discovery.
[159] K. Jacobson. Structure-based approaches to ligands for G-protein-coupled adenosine and P2Y receptors, from small molecules to nanoconjugates. , 2013, Journal of medicinal chemistry.